Physician profile
Steven D Eilen
NPI 1346249059
$3,053.44
in general payments reported to CMS, 2019-2025
23 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $145 · 2021: $263 · 2022: $558 · 2023: $576 · 2024: $494 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.42 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $345.02 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $288.79 | 2019-2024 | Xarelto |
| Amgen INC. | $248.11 | 2019-2024 | Repatha |
| Actelion Pharmaceuticals US, INC. | $231.78 | 2019-2023 | Opsumit |
| Astrazeneca Pharmaceuticals LP | $231.59 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $191.99 | 2022-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $191.82 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $182.60 | 2021-2025 | |
| Cvrx, INC. | $165.99 | 2025 | Barostim Neo System |
| Pfizer INC. | $149.58 | 2022-2024 | |
| Esperion Therapeutics, INC. | $139.97 | 2021-2025 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $126.81 | 2019-2022 | |
| Boston Scientific Corporation | $121.98 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $110.01 | 2019-2024 | Eliquis |
| Novo Nordisk INC | $83.07 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $64.80 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Gilead Sciences, INC. | $50.82 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $37.44 | 2023-2024 | Inpefa |
| Bridgebio Pharma, INC. | $22.04 | 2025 | Attruby |
| United Therapeutics Corporation | $20.24 | 2020-2021 | |
| Amarin Pharma, INC. | $20.14 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.02 | 2019 | |
| Scpharmaceuticals INC. | $13.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Eilen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.